A phase Ib study of BL-8040 in combination with Atezolizumab in patients with gastric cancer

Trial Profile

A phase Ib study of BL-8040 in combination with Atezolizumab in patients with gastric cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary) ; BL 8040 (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 06 Jun 2017 New trial record
    • 01 Jun 2017 According to a BioLineRx media release, Genentech has filed regulatory submissions required to commence this trial and the company expects to initiate this trial in the second half of 2017 after receipt of regulatory approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top